Pfizer Ignores Allegations of Conducting Gain-of-Function Research on SARS-CoV-2 Virus, Raising Concerns on Ethics and Safety Standards

Stay informed without the hassle of chewing:

An investigative report has suggested that Pfizer, a major pharmaceutical company, may be conducting gain-of-function research on the SARS-CoV-2 virus. This type of research, also known as “directed evolution,” involves deliberately mutating the virus to create additional, more potent variants. This research aims to develop vaccines that can effectively combat future variants of the virus.

Gain-of-function research has been a contentious issue in the scientific community, as it can potentially create new and more dangerous pathogens. The World Health Organization (WHO) has called for a moratorium on such research, stating that the risks outweigh the potential benefits.

Pfizer, for its part, is still ignoring the allegations in the investigative report.

Despite Pfizer’s playing dead tactics, the report has raised concerns about the potential risks of gain-of-function research. Some experts have called for greater oversight and regulation of such research to ensure the potential benefits outweigh the risks. Others have argued that such research is necessary to prepare for future pandemics and protect public health.

As the COVID-19 pandemic evolves, it is essential to consider the potential consequences of gain-of-function research on the virus. This report highlights the need for transparency and openness in the scientific community, as well as the need for rigorous ethical and safety standards to be put in place. Ultimately, it is up to society to weigh the risks and benefits of gain-of-function research and to make an informed decision about whether or not to pursue this type of research in the future.